Backwardation, Buybacks and a Chemical Kitchen: Chord Rewrites Its Base-Decline Curve
War-driven Bakken premiums and a leaner balance sheet unlock a 75% payout floor, while an expanded in-house chemical-workover program attacks ~5,000 aging wells.
CHRD · Earnings Call · 2026-08-06
The 75% payout floor arrives on a war-tilted curve
The macro backdrop to Chord's second quarter is unusual for a Bakken producer: war-driven backwardation flipped the basin's crude from a habitual discount into a rare premium to WTI. Chief Strategy Officer Michael Lou described the mechanics bluntly — “with the huge run-up in oil price in the second quarter because of the war, we saw a huge backwardation in the curve... you saw some of that CMA roll kind of roll through to better differentials.” — Michael Lou, Chief Strategy Officer and Chief Commercial Officer · 2026-08-06 Chord's guidance now embeds oil realizations just below WTI for the back half — roughly parity versus the multi-dollar discounts the basin has shrugged off for years. That is one of the quiet value shifts in this print.
The bigger change is what Chord does with the windfall. After returning 54% of Q2 adjusted free cash flow ($220 million), management is pulling the trigger on a long-promised escalation:
As we drop below this 0.5 turn levered on our normalized pricing basis, we've committed we'll return at least 75% back to shareholders... I would fully anticipate we'll be above 75% at a floor of 75% for the balance of the year.
That pivot reads differently against the prior quarter's caution. In May, Danny Brown insisted the company “we are not fans of procyclical buybacks” — Danny Brown, Chief Executive Officer · 2026-05-06 — code for preferring countercyclical repurchases. Now, with the balance sheet grown to $612 million and the stock still ~21% below its 2024 peak, Chord is leaning in at high prices rather than hedging out. The valuation math supports it: at ~4.3x trailing free cash flow, with a ~30% free cash flow margin, shares are cheap even near cycle-high prices, and Q1's $499M of free cash flow sits close to its all-time peak.
The real news: an industrial-scale chemical program on ~5,000 wells
Skim the analyst questions and one theme dominates: the chemical program. This is Chord's genuinely company-specific frontier, and it is new. In February, Darrin Henke told the Street the team had "pumped 19 chemical and surfactant treatments already" “and we are evaluating those results” — Darrin J. Henke, Chief Operating Officer · 2026-02-26. Five months later, Chord is testing multiple chemical treatments across a far larger subset of its ~5,000-well PDP base, lowering rod pumps, arresting decline on a meaningful cohort, and running a fleet of workover rigs at 24-hour operations.
The economics are deliberately asymmetric — a little LOE in exchange for short-cycle barrels. Danny Brown: “If investing a small amount of incremental LOE in short-cycle opportunities today has a high probability of generating strong risk-adjusted cash flow in the future, that's exactly the type of investment we want to make.” — Daniel Brown, Chief Executive Officer · 2026-08-06 That is why full-year LOE guidance rose to $10.30/BOE — a rare guided cost increase for a company that has spent three years grinding costs down. The prize is a fatter, flatter base-decline curve: Chord raised its full-year oil guide by 2,000 bbl/d to 161,000 bbl/d and, per its Slide 6, has arrested the decline on a good chunk of legacy wells.
Underneath the chemicals sits the AI layer. Chord has broadly deployed machine-optimized rod pump control — "almost every well that we've got within the field will end up on rod pump," Brown noted, with “the ability of the computer through artificial intelligence to really optimize that entire rod pump program” — Daniel Brown, Chief Executive Officer · 2026-08-06 — and is rolling the same logic into workover rig scheduling, turning what was human dispatch judgment into run time math across a field with wells going down daily. Management is explicit, though, that none of the chemical uplifts are yet in guidance: “early results have been encouraging... we need to see the production hang in for a little longer before we can start really hanging sort of full expectations to it” — Daniel Brown, Chief Executive Officer · 2026-08-06 — honesty that keeps the option value on Chord's side of the ledger.
The efficiency machine keeps turning: 4-mile laterals and trimulfracs
The mile program remains the compounding driver of Chord's cost of supply. Chord has turned in line 26 four-mile wells, and Darrin Henke flagged the basin's first trimulfrac for real scale — “it could be 25% to maybe as much as 50% of our program next year.” — Darrin Henke, Unknown · 2026-08-06 The economics hinge on the 4th mile: Chord still underwrites roughly 80% contribution from that last mile and is waiting on stabilized flow data before validating it the way it did for three-mile wells, even as downhole tracers confirm the toe stages are contributing.
Put the pieces together and Chord is running two parallel value engines: the macro (war-backwardation into the best differentials the basin has seen) and the micro (an industrial program to squeeze more oil from a massive, low-decline, AI-managed PDP base, bought back at 4.3x FCF and returned to shareholders at a 75% floor). The stock is up ~10% over three months on the oil bid but has not yet re-rated. If the chemical program works at scale, the base-decline curve gets flatter, free cash flow per share turns up another notch, and the drawdown from the 2024 peak starts to look like a rounding error.